About PROCEPT BioRobotics

PROCEPT BioRobotics is a privately held medical device company committed to providing surgeons with innovative new technology for the treatment of men with prostate disease. The Company’s first product developed is the AquaBeam, an intelligent image-guided robotic system delivering Aquablation, a waterjet tissue resection modality. The AquaBeam is currently for investigational use only in the United States and is not marketed for sale. PROCEPT is headquartered in Redwood Shores, California.

Board of Directors

Rodney Perkins, M.D.
Co-founder and Chairman of the Board

Dr. Perkins is an internationally known ear surgeon, the founder of the California Ear Institute at Stanford and a successful serial medical device entrepreneur. He is the founder of three public companies: Collagen, Laserscope, and ReSound, and was chairman of the latter two. He is or was founder or co-founder and chairman of Cohesion, Novacept, Pulmonx, Sound ID, Surgrx, Define, Minerva, Iogyn and Soundhawk.

Dr. Perkins received the Phoenix Hall of Fame Innovation Award and the Lifetime Achievement Award from Medical Futures, a British organization that fosters innovation in medicine. He is a graduate of the Indiana University School of Medicine where he recently received the Distinguished Medical Alumnus Award. Dr. Perkins is a Clinical Professor of Surgery at Stanford and holds over 40 patents.

Nikolai Aljuri, Ph.D.
Co-founder, President and CEO

Dr. Aljuri is the principal architect of the AquaBeam technology. Prior to the formation of Procept he developed the Chartis collateral ventilation assessment technology at Pulmonx that facilitated an effective therapeutic treatment for emphysema. At the NASA Center for Quantitative Cardiovascular Physiology and Data Analysis he worked on the physiologic implications for astronauts in the manned space mission to Mars.

Dr. Aljuri has a Dipl.-Ing. in electrical engineering from the Universität Fridericiana zu Karlsruhe (KIT) in Germany and holds a Ph.D. in Medical Physics from the Harvard-MIT Division of Health Science and Technology at the Massachusetts Institute of Technology (MIT).

Frederic Moll, M.D.
Director

Dr. Moll is the founder, Chairman and CEO of Auris Surgical Robotics. Prior to Auris he was co-founder of Hansen Medical, Restoration Robotics and founder and first CEO of Intuitive Surgical, the world leader in surgical robotics, and a major player in urology. Dr. Moll was a co-founder of Origin Medsystems, and served as the Medical Director of Guidant's Surgical Device Division. Early in his career he founded Endotherapeutics, a pioneering company in laparoscopic surgical technology.

Dr. Moll holds a B.A. degree from the University of California at Berkeley, an M.S. degree in management from Stanford University, and an M.D. degree from the University of Washington.

Eric N. Shiozaki, Ph.D.
Director

Mr. Shiozaki joined Novo Ventures (US) Inc. in San Francisco, California in 2014. Prior to joining Novo Ventures (US) Inc., he was a Director at Apposite Capital where he established the firm’s San Francisco office and managed its secondary direct investment activity in the US. He has also worked for Vitapath Genetics in Business Development and Strategy, and as an Associate at Burrill & Company where he was a member of the firm’s venture capital practice. Before entering venture capital, Mr. Shiozaki was a Leukemia & Lymphoma Society Post-Doctoral Fellow at UCLA. While conducting his post-doctoral research, he also spent time in the University’s technology transfer office.

Mr. Shiozaki received a PhD in Molecular Biology from Princeton University, and a BA in Biophysics from Johns Hopkins University.

Eric Reuter
Director

Mr. Reuter is a medical device executive with nearly 30 years of product design and development, project management, and executive management experience in both public and private companies. Most recently, he was president, CEO of Satiety, a private, venture-backed company focused on developing a minimally invasive solution for obesity. Prior to Satiety, he was president, CEO of Laserscope, a leading company in urology with the Green Light laser. Also, Mr. Reuter served as the independent director at Insound. In his early career he was the Project Engineer in the B-Factor high energy research project at the Stanford Linear Accelerator Center and an engineer at Siemens Medical Systems.

Mr. Reuter received his BS degree in Mechanical and Materials engineering from UC Davis.

Antal Desai
Director

Mr. Desai is a partner at CPMG, Inc. CPMG is an investment firm that employs a concentrated, value-oriented approach to investing in publicly traded and private operating companies. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Mr. Desai worked as an analyst at WhiteHorse Capital Partners, L.P. He currently serves on the Board of Directors of Procept BioRobotics Corporation, ESN Venture Holdings LLC, Lifeblue Incorporated, and Travel Research Advisors LLC. Mr. Desai holds a B.S. and an M.B.A. from The Wharton School at the University of Pennsylvania.

Colby Wood
Director

Mr. Wood is a Portfolio Manager and Research Analyst for Oechsle International Advisors in London where he is responsible for medical technology investments globally. Prior to this current position, he was with Freeman & Company, a boutique M&A advisory firm focused on the financial services industry. Earlier in his career Mr. Wood was actively involved as an investor, asset gatherer and business development executive for early stage companies in financial services and medical technology sectors.

Mr. Wood holds a B.A. from the University of Delaware and an MBA in Finance and Entrepreneurship from the F.W. Olin Graduate of Business at Babson College.

Thomas Krummel, M.D.
Director

Dr. Krummel is the Surgeon-in-Chief at Lucile Packard Children’s Hospital and Chairman of the Surgery Department at the Stanford University School of Medicine, He is the founder of the Surgical Innovation Program at Stanford, and Co-Director of the Stanford Biodesign Program which teaches innovation and implementation of new surgical technologies. The program has spawned 35 start-ups which have received more than $300 million in follow-on financing.

Dr. Krummel has lectured throughout the world and is author or co-author of over 300 publications, chapters, abstracts and books. He is on the board of the Fogarty Innovation Institute and has served on the board of directors or scientific advisory boards of 15 medical device start-ups.

Management

Nikolai Aljuri, Ph.D.
President and CEO

Dr. Aljuri is the principal architect of the AquaBeam technology. Prior to the formation of Procept he developed the Chartis collateral ventilation assessment technology at Pulmonx that facilitated an effective therapeutic treatment for emphysema. At the NASA Center for Quantitative Cardiovascular Physiology and Data Analysis he worked on the physiologic implications for astronauts in the manned space mission to Mars.

Dr. Aljuri has a Dipl.-Ing. in electrical engineering from the Universität Fridericiana zu Karlsruhe (KIT) in Germany and holds a Ph.D. in Medical Physics from the Harvard-MIT Division of Health Science and Technology at the Massachusetts Institute of Technology (MIT).

Surag Mantri
Sr. Vice President, Research and Development

Mr. Mantri has over 15 years of medical device experience which includes design and development, clinical validation, EU/FDA regulatory approval, commercialization, sales/marketing support, and post-commercial technical & clinical training. Prior to his tenure at Procept, Mr. Mantri managed and provided engineering solutions to a diverse set of projects including embolic protection, insulin delivery, continuous glucose monitor, reconstructive surgical implant, cardiovascular implant, ophthalmic implant for glaucoma, endoscopic RF toolset, lung implant, diagnostic system for lung function, fall-detection wearable, and robotic-assisted surgical devices.

Mr. Mantri received a B.S. degree in Computer Science, M.S. in Bioinformatics, and M.S. in Bioengineering from Stanford University. He has over 25 patent and patent applications.

Matthew Salkeld
Vice President, Sales and Marketing

Mr. Salkeld has 20 years in the medical device industry in a variety of functions including Sales and Sales Management, Strategy and Product Marketing, Clinical Market Development, and Finance. Prior to joining Procept, Mr. Salkeld spent seven years at Acclarent, a company focused on solutions in the field of ENT which was acquired by Johnson & Johnson in 2010. Following the acquisition, Mr. Salkeld was a member of the Acclarent executive team with responsibilities including US Sales, WW Marketing, & Professional Education. Prior to these roles, he was an Area Sales Director at Acclarent leading the Western Area in sales strategy and execution. Prior to Acclarent, Mr. Salkeld had extensive experience in the cardiovascular area with executive Sales & Marketing positions at Cierra, Inc. and Vascular Architects, as well as a variety of roles at Guidant, which was acquired by Abbott Vascular. Prior to Guidant, Mr. Salkeld was a Manager at Ernst & Young, LLP.

Mr. Salkeld holds a BS in Commerce and an MBA from Santa Clara University.

Daniel Cher, M.D.
Vice President, Quality, Regulatory Affairs and Biostatistics

Daniel Cher is a board-certified internist with over 15 years of clinical affairs and research experience in a variety of medical device technology companies. His experience includes developing clinical and regulatory strategy, designing and leading clinical trials, directing clinical research, and consulting with a variety of medical device technology companies.

Most recently, he has served as VP of Clinical Affairs at SI-Bone, a medical device company developing a minimally invasive surgical device indicated for the fusion for certain disorders of the sacroiliac joint. Prior to SI-Bone, Dr. Cher was VP of Clinical and Regulatory Affairs at Chestnut Medical, an early-stage company developing new minimally invasive therapies for Interventional Neuroradiology. Prior to this, Dr. Cher served as VP of Clinical and Regulatory Affairs at Pulmonx, Inc., and was Medical Director and VP of Clinical Research at Kyphon, Inc., where he directed clinical research.

Educated at Stanford and Yale Universities, Daniel pursued his residency in internal medicine at University of Wisconsin, Madison, and California Pacific Medical Center, in San Francisco. Daniel underwent additional training in general internal medicine and research methods at Stanford University and the Palo Alto VA Hospital. Daniel left clinical practice in 1999 to lead clinical trials at several San Francisco Bay Area medical device technology companies, including Kyphon. Daniel's focus is on clinical trial design and statistical analysis.

Barry Templin
Vice President, Clinical Affairs

Mr. Templin joined Procept in 2016. He has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, prior to his current role with Procept, Mr. Templin served as the Vice President of Clinical Research, Engineering, and Therapy Development for CardioKinetix developing a novel technology for ischemic heart failure. Prior to CardioKinetix, Mr. Templin served as the Global Clinical Program Director for Abbott Vascular. In that role, he led multiple coronary and endovascular trials (DES, BMS, Bioresorbable, and BDC), interfaced with clinical thought leaders, and is published in medical journals. In addition, he led the landmark vulnerable plaque natural history study, PROSPECT, which is now published in the NEJM. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines (Six Sigma Project Leader) and Guidant (DES Product Development), and then clinical positions with Guidant (that was later acquired by Abbott).

Mr. Templin holds a BS in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology, MBA from Duke, and certifications in Advanced Project Management and Organizational Design through Stanford University.

Christine Hänni
Chief Financial Officer

Ms. Hänni has over 25 years experience in the financial industry with 20 years specifically in the medical device industry. Christine has been providing consulting CFO services to early-stage medical device and technology companies for the last 13 years. Christine was VP Finance and CFO at ArthroCare Corporation, a medical device company that develops, manufactures and markets products for a variety of soft tissue surgical applications. Formerly, Ms. Hanni worked at Target Therapeutics, a medical device enterprise focused in the neuro-interventional market. Early in her career she worked for Tandem Computers and for PricewaterhouseCoopers. Christine holds a Bachelor of Science degree in Business Administration/Accounting.

Eric Steuben
Vice President, Operations

Eric Steuben is an energetic leader with over 25 years of progressive achievements from hands-on engineering to executive management. He has broad corporate experience ranging from high-growth start-ups and world-leading corporations. Eric has successfully transferred manufacturing operations offshore to China, Mexico, Pakistan, Dubai, and Costa Rica. Prior to joining Procept, he held executive leadership roles in manufacturing, operations, regulatory affairs and quality assurance with Clarity Medical Systems, Asante Solutions, Align Technology and MicroDental Laboratories. He started his career at Varian Medical. Eric holds both a BS degree in Mechanical Engineering and a Masters degree in Business Administration from Santa Clara University.

Kevin Staid
Vice President, Engineering

Mr. Staid has extensive experience in the conception, development, and manufacture of medical devices. He was founder and innovator at HydroCision developing the core pumping and fluid jet technology, and worked extensively with medical leaders conceiving and fabricating end user devices for surgical fluid jet products in the fields of wound, arthroscopy, and spine. Mr. Staid engaged with leaders in the fields exploring markets and developing devices in cosmetics, gynecology, urology, and neurosurgery.  Previous rolls included engineering and operations positions at CR Bard, American Surgical Technology, and J&J. His experience and knowhow add significantly to the depth and innovation at Procept BioRobotics.

Mr. Staid studied Mechanical Engineering at University of Massachusetts - Lowell and received a B.S. Management from Lesley University.  He has many patents and patent applications.